Acumen Pharmaceuticals Inc

NASDAQ:ABOSUnited States

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. It is developing ACU193 for intravenous (IV), administration every four weeks for the treatment of early AD, which is in Phase I clinical trial.

Contact Information

Headquarters

427 PARK ST.CHARLOTTESVILLE, VA, United States 22902

Phone

925-368-8508

Fax

302-636-5454

Executives

President, Chief Executive Officer, Director

Daniel O'Connell

Co-Founder, Chief Scientific Advisor

Grant Krafft

Chief Financial Officer, Chief Business Officer

W. Matthew Zuga

Chief Operating Officer

Russell Barton

Chief Medical Officer

Eric Siemers